KEDRAB® (Rabies Immune Globulin [Human]) is a biologic prepared by chromatographic fractionation from a pool of plasma collected from selected US adult human donors who have been immunized with rabies vaccine and have developed high titers of anti-rabies antibody.1
KEDRAB is derived from human plasma; therefore, the potential exists that KEDRAB administration may transmit infectious agents such as viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.2
If you are interested in receiving the most current information about KEDRAB, proper PEP, and educational rabies resources, enroll now.
References: 1. Data on file. Kamada Ltd. 2. KEDRAB [package insert]. Fort Lee, NJ: Kedrion Biopharma Inc.; 2021. 3. FDA acceptance of BLA submission for human rabies immunoglobulin [press release]. Fort Lee, NJ/Ness Ziona, Israel: November 8, 2016.